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Abstract
Receptor activator of nuclear factor kappa-B (RANK)-RANK ligand (RANKL) signaling 
promotes mammary tumor development in experimental models. Circulating concentrations of 
soluble RANKL (sRANKL) may influence breast cancer risk via activation of RANK signaling; 
this may be modulated by osteoprotegerin (OPG), the decoy receptor for RANKL. sRANKL and 
breast cancer risk by hormone receptor subtype has not previously been investigated.
A case-control study was nested in the European Prospective Investigation into Cancer and 
Nutrition (EPIC) cohort. This study included 1976 incident invasive breast cancer cases (estrogen 
receptor positive (ER+), n=1598), matched 1:1 to controls. Women were pre- or postmenopausal 
at blood collection. Serum sRANKL was quantified using an enzyme-linked immunosorbent 
assay, serum OPG using an electrochemiluminescent assay. Risk ratios (RRs) and 95% confidence 
intervals (95%CIs) were calculated using conditional logistic regression.
Associations between sRANKL and breast cancer risk differed by tumor hormone receptor status 
(phet 0.05). Higher concentrations of sRANKL were positively associated with risk of ER+ breast 
cancer (5th vs. 1st quintile RR 1.28 [95%CI 1.01-1.63]; ptrend 0.20), but not ER- disease. For both 
ER+ and estrogen and progesterone receptor positive (ER+PR+) breast cancer, results considering 
the sRANKL/OPG ratio were similar to those for sRANKL; we observed a suggestive inverse 
association between the ratio and ER-PR- disease (5th vs. 1st quintile RR 0.60 [0.31-1.14]; ptrend 
0.03).
This study provides the first large-scale prospective data on circulating sRANKL and breast 
cancer. We observed limited evidence for an association between sRANKL and breast cancer risk.
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Introduction
The receptor activator of nuclear factor kappa-B (RANK) axis includes three tumor necrosis 
superfamily members; a transmembrane receptor (RANK), its only known ligand (RANKL) 
and a decoy receptor for RANKL (osteoprotegerin, OPG). The RANK-axis was first 
described in relation to its role in bone metabolism; the interplay between RANK, RANKL, 
and OPG regulates osteoclast development and activation, and is essential in bone 
homeostasis (1).
RANK and OPG are expressed in multiple tissues and organs such as the adrenal gland, 
small intestine, thymus, and the breast (2–4). RANKL is highly expressed in lung and lymph 
nodes and is found at lower levels in numerous other tissues including skeletal muscle, 
placenta, and heart (2). OPG and RANKL (in its soluble form, sRANKL) are also found in 
circulation (3–5).
RANKL expression in mammary epithelial cells is upregulated in pregnancy, and is essential 
for development of the lobulo-alveolar mammary structures and the formation of a lactating 
mammary gland (3,6,7). In experimental models, the synthetic progesterone analogue 
medroxyprogesterone acetate (MPA) induces RANKL expression in PR+ luminal mammary 
epithelial cells, resulting in auto-/paracrine stimulation of RANKL signaling in the 
mammary epithelium (8,9). This triggers proliferation of mammary epithelial cells, 
expansion of mammary stem cells, and shields these cells from apoptosis, which results in 
increased rates of tumor formation (8,9). In the human breast, expression of RANKL is 
regulated by sex hormones and may be induced by progesterone and prolactin (3,10,11). 
RANKL expression in the human breast is correlated with high serum progesterone levels, 
and is required for progesterone-induced proliferation (10).
Human epidemiologic data on the RANK-axis and breast cancer risk is limited. Four studies 
to date have investigated circulating OPG (12–15) and breast cancer risk, one of which in a 
population of high-risk women (14). Only one study, conducted by our group, has 
investigated OPG and breast cancer risk by hormone receptor subtype (12). We observed a 
significant positive association between OPG concentrations and estrogen receptor (ER) 
negative disease in the European Prospective Investigation into Cancer and Nutrition (EPIC) 
cohort, yet only a suggestive inverse association for ER positive cancers (3rd vs. 1st tertile 
RR: ER- 1.93 [95%CI 1.24-3.02]; ptrend 0.03 and ER+ 0.84 [95%CI 0.68, 1.04]; ptrend 0.18. 
n=2008 total breast cancer cases) (12). Vik et al. observed a significant inverse association 
between OPG and breast cancer risk overall among 76 breast cancer cases (13) as did Odén 
et al, in a small cohort of BRCA1 and BRCA2 carriers (18 breast cancer cases) (14). In the 
only study to date to evaluate sRANKL and breast cancer risk, Kiechl et al., reported a 
positive association between sRANKL and breast cancer risk in postmenopausal women 
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with relatively high circulating progesterone concentrations diagnosed 12-24 months after 
blood collection (n=21 cases in this subgroup) (15).
The RANK-axis has gained interest in breast cancer research as denosumab, a monoclonal 
antibody that inhibits RANKL, has been shown to reduce the number of skeletal related 
events (e.g., pathologic fracture) in cancer patients with bone metastasis (16) and has been 
suggested as a candidate for breast cancer prevention in women at high risk (17). Following 
our investigation of OPG in breast cancer (12), we conducted the first large-scale 
investigation on sRANKL and the sRANKL/OPG ratio and breast cancer risk in a nested 
case-control study in the EPIC cohort.
Methods
The European Prospective Investigation into Cancer and Nutrition (EPIC) started in 
1992-2000 and follows 520,000 healthy adults (367,993 women) aged 35-75 years from 23 
centers in 10 European countries (18). Incident cancer cases were identified through cancer 
registries in Denmark, Italy (except Naples), the Netherlands, Norway, Sweden, Spain, and 
the UK, and through review of health insurance records, contact with cancer and pathology 
registries, and/or direct contact with cohort members in France, Germany, Greece and the 
Naples, Italy center. Mortality data were obtained via active follow-up in Germany and 
Greece, and via national and regional mortality registries in the remaining countries.
Detailed dietary, reproductive, lifestyle, anthropometric, and medical history data were 
collected through standardized methods. The majority of women (64%; n=235,607) gave a 
blood sample. Blood samples were collected according to standardized protocols. For all 
countries, except Denmark and Sweden, half of the aliquots were stored locally and the other 
half centrally at the International Agency for Research on Cancer (IARC). The samples used 
in this study were stored at IARC are stored under liquid nitrogen at -196°C, or locally at 
-150°C for Danish participants. Participants from Sweden were not included in this study, as 
independent studies on breast cancer risk were conducted in those centers.
The study protocol for this study was approved by the ethical committees of the 
International Agency for Research on Cancer (IARC, Project No. 12-42) and the University 
of Heidelberg (Project No. S311/2014). The EPIC study protocol was approved by the 
ethical committees of IARC and the participating centers. All participants gave written 
informed consent.
Nested case-control study
This study used a case-control design nested within the EPIC cohort. The study design and 
methods have been described previously (12,19,20). Briefly, breast cancer cases included in 
this case-control study were female and were diagnosed with a first invasive breast cancer 
between blood collection and completion of last follow-up, which ranged from 2003 to 2006 
between centers. Both pre- and postmenopausal women were included; premenopausal 
women were all non-users of oral contraceptives/exogenous hormones at blood collection, 
whereas postmenopausal women include both postmenopausal hormone (PMH) users and 
non-users. Prior to 2004, all cases with available ER status were included. From 2004, 
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among postmenopausal women, all incident ER- cases were included along with one ER+ 
case for every ER- case (matched on center). This investigation is limited to cases with ER 
status available; progesterone receptor (PR) status was available for 74% of cases. Controls 
were randomly selected from cohort participants who donated a blood sample and were alive 
and cancer free (except non-melanoma skin cancer) at the time of diagnosis of the index 
case. Controls were matched on recruitment center, age (±3 months), menopausal status, 
PMH use, fasting status (<3; 3-6; >6 hours), and time of the day (±1 hour) at blood donation. 
Premenopausal cases and controls were also matched on menstrual cycle phase at blood 
donation (early follicular, late follicular; peri-ovulatory, early luteal, mid luteal, late luteal). 
A total of 2020 case-control sets were selected for the present study.
Laboratory analyses
Concentrations of sRANKL (soluble homotrimeric form of RANKL) and OPG were 
analyzed at the Laboratory of the Division of Cancer Epidemiology at the German Cancer 
Research Center (DKFZ). Serum OPG was quantified using an electrochemiluminescence 
assay (MesoScale Diagnostics, USA). Serum sRANKL was analyzed in duplicate, using an 
enzyme-linked immunosorbent assay (Biomedica, Austria). Samples from cases and their 
matched controls were analyzed in the same analytical batch and laboratory personnel were 
blinded to the case-control status of the samples. The precision of the laboratory work was 
monitored by inclusion of blinded pooled quality control samples (2 per batch). Inter-batch 
coefficients of variation were 0.9% for premenopausal and 1.5% in postmenopausal women 
for sRANKL and 16.4% and 16.8%, respectively, for OPG. Intra-batch coefficients of 
variation for sRANKL were 15.6% for pre- and 13.3% for postmenopausal women. For 
OPG these were 9.0% and 21.7% respectively.
Assays for estradiol, estrone, testosterone, sex hormone-binding globulin (SHBG), insulin-
like growth factor I (IGF-I), prolactin, progesterone, vitamin D and C-peptide in subsets of 
participants (n=611 to 2020) in the present study were previously conducted at the 
International Agency for Research on Cancer (IARC) and the German Cancer Research 
Center (DKFZ) (19–24).
Of the 2020 case-control sets initially selected for the present study, sRANKL 
concentrations were not available for 44 total case-control sets (38 sets, equipment failure 
and insufficient sample volume to re-assay; 6 sets, missing values). A total of 1976 case-
control sets remained for sRANKL analyses. For analyses including OPG, an additional 9 
case-control sets were excluded (4 sets, missing values; 5 sets excluded due to outlying OPG 
values); 1967 case-control sets were included for sRANKL/OPG ratio analyses. 327 
observations (8.1%; 175 cases, 152 controls) were below the limit of detection for sRANKL. 
These were set to 50% of the lower limit of detection of the assay (LLOD; 0.01pmol/L).
Statistical analyses
Concentrations of sRANKL and OPG (both in in pmol/L), as well as the other available 
biomarkers, were log2 transformed to obtain approximately normal distributions. This 
transformation also allowed evaluation of the effect of a doubling in biomarker 
concentrations. The extreme studentized deviate test was used to evaluate outliers (25). The 
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ratio was calculated as sRANKL concentration divided by OPG concentration; the ratio was 
then log2 transformed.
Cross-sectional correlations between sRANKL and endogenous hormones by menopausal 
status and postmenopausal hormone use at blood collection were assessed among study 
controls using partial Spearman correlations, adjusting for matching factors. sRANKL and 
the sRANKL/OPG ratio were classified into quintiles based on their distribution in controls. 
Conditional logistic regression was used to estimate risk ratios (RR) and 95% confidence 
intervals (CI) for breast cancer risk. Tests for trend were conducted using the continuous 
(log2) variables.
Multivariable models were adjusted for BMI (continuous; allowing separate associations by 
menopausal status), number of full term pregnancies (0, 1, 2, ≥3, missing), and ages at 
menarche (≤12, 13, 14, ≥15, missing), first full term pregnancy (no full term pregnancy, ≤25, 
25-29, ≥30, missing), and menopause (≤43, 44-47, 48-50, 51-52, 53-54, ≥55, missing). 
Additional adjustment for lifestyle and reproductive factors (e.g. smoking status, alcohol 
consumption, physical activity, use of exogenous hormones, breastfeeding) and endogenous 
hormones did not change the effect estimate by a factor of 1.10 (or the reciprocal). In 
addition to evaluating the sRANKL/OPG ratio, we evaluated the association between 
sRANKL and breast cancer, adjusted for OPG as a covariate in the logistic regression 
models, and evaluated the joint distribution of sRANKL and OPG by cross-classifying both 
markers at the median value (e.g., comparing sRANKL >median/OPG <median to sRANKL 
<median/OPG >median).
We assessed heterogeneity by reproductive and lifestyle factors (e.g. menopausal status, use 
of exogenous hormones, number of full term pregnancies, smoking status) and endogenous 
hormones (high vs. low concentrations, divided at median in controls; progesterone, 
testosterone, estrogen, estradiol) using likelihood ratio tests to compare models in- and 
excluding interaction terms with these factors. For hormone receptor status and age at 
diagnosis (<50 vs. ≥50 years), we assessed potential heterogeneity using polytomous 
conditional logistic regression models comparing models assuming the same association 
versus different associations between sRANKL or the sRANKL/OPG ratio and breast cancer 
subgroups (e.g. ER+ and ER-) (26). A sensitivity analysis excluding cases diagnosed within 
two years of blood collection (n=367, 19%) was performed to address the possibility of 
reverse causation.
All statistical tests were two-tailed and considered significant at p<0.05. Statistical analyses 
were conducted using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
Reproducibility study
A reproducibility study was conducted in 221 women who were randomly selected from the 
592 EPIC-Heidelberg participants who donated blood samples at baseline (1994-1998) and 
after 14 years and 15 years of follow-up. Both the EPIC-Heidelberg cohort and the 
reproducibility study have been described previously (12,27). One-year (between 14 and 15 
years of follow-up) and fourteen-year (between baseline and 14 years of follow-up) 
reproducibility of sRANKL and OPG was assessed using Spearman correlation coefficients. 
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Results for within-person reproducibility for OPG (r=0.85 over one year and r=0.75 over 14 
years) have been published previously (12).
Results
At blood collection, the majority of the study population (77%) was postmenopausal, and 
half of the postmenopausal women (758 case-control sets, 50%) were using exogenous 
hormones (Table 1). Median age at blood collection was 56 years (range 27-77 years), and 
median age of diagnosis for cases was 61 years (range 35-84 years). Among cases, 81% 
were ER+ and 19% were ER-.
Adjusting for matching factors, sRANKL concentrations were weakly to moderately 
inversely correlated with OPG concentrations among study controls (e.g., premenopausal 
women, Spearman r= -0.40). Concentrations of sRANKL were not, or only weakly 
(Spearman r<|0.30|), correlated with age, body mass index (BMI, kg/m2) or the other 
evaluated hormones (Supplementary table 1). With the exception of variation by age and 
menopausal status at blood collection, the distribution of covariates was similar between 
sRANKL quintiles for both cases and controls (Supplementary table 2).
There was suggestive heterogeneity in the association between sRANKL and breast cancer 
risk by hormone receptor status (ER+PR+ vs. ER-PR- phet 0.05; ER+ vs. ER- phet 0.13) 
(Table 2). sRANKL was suggestively associated with ER+PR+ breast cancer (5th vs. 1st 
quintile RR 1.36 [95%CI 0.99-1.87]; ptrend 0.31) and significantly associated with ER+ 
disease (5th vs. 1st quintile RR 1.28 [1.01-1.63]; ptrend 0.20). We observed no association 
between sRANKL and hormone receptor negative disease (e.g. ER- 5th vs. 1st quintile RR 
0.87 [0.53-1.44]; ptrend 0.21). There was no heterogeneity by age at diagnosis (<50 vs. ≥50 
years phet ≥0.52), however, associations of sRANKL with ER+ and ER+PR+ disease were 
only observed in women who were diagnosed at an older age (age ≥50 years, 5th vs. 1st 
quintile: RR ER+ 1.33 [1.03-1.70]; ptrend 0.22 and ER+PR+ 1.44 [1.02-2.03]; ptrend 0.33).
The association between the sRANKL/OPG ratio and breast cancer risk differed 
significantly by hormone receptor status (ER+PR+ vs. ER-PR- phet 0.02; ER+ vs. ER- phet 
0.05). A higher sRANKL/OPG ratio was associated with increased risk of ER+ breast cancer 
(5th vs. 1st quintile RR: ER+ 1.33 [1.03-1.71]; ptrend 0.12 and ER+PR+ 1.42 [1.01-1.98]; 
ptrend 0.21) (Table 3). We observed a significant trend suggesting an inverse association 
between the sRANKL/OPG ratio and ER-PR- disease (ptrend 0.03); however, we observed no 
significant association in the quintile contrast (5th vs. 1st quintile RR 0.60 [0.31-1.14]). 
Similar to sRANKL, there was no heterogeneity by age at diagnosis (<50 vs. ≥50 years phet 
≥0.43); however, associations between the sRANKL/OPG ratio and ER+ and ER+PR+ 
disease remained significant only in those aged ≥50 years at diagnosis (5th vs. 1st quintile 
RR: ER+ 1.34 [1.03, 1.75]; ptrend 0.14) and ER+PR+ 1.44 [1.00-2.06]; ptrend 0.25). We 
observed no heterogeneity by menopausal status at blood collection (Supplementary tables 3 
& 4).
Associations between sRANKL and breast cancer risk were similar before and after 
adjusting for OPG concentrations (e.g. 5th vs. 1st quintile RR ER+PR+: before adjustment: 
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1.36 [0.99-1.87] and after adjustment: 1.32 [0.94-1.85]) (Supplementary table 5). No 
associations were seen in analyses considering the cross-classification of sRANKL and OPG 
concentrations (e.g. high sRANKL and low OPG vs. low sRANKL and high OPG RR: ER
+PR+ 1.04 [0.87-1.24]) (Supplementary table 6).
Additional adjustment for endogenous hormone concentrations and reproductive and 
lifestyle factors did not change the interpretation of results. We observed no effect 
modification by circulating estrogens, progesterone, testosterone, prolactin, smoking status, 
ever use of OCs or PMH, use of PMH at blood collection, or ever having had a full term 
pregnancy (pint ≥0.06). Excluding women diagnosed within two years of blood donation in 
sensitivity analyses did not impact the results (data not shown).
Spearman correlations of sRANKL concentrations over one year were r=0.60; correlations 
between concentrations in samples taken 14 years apart were r=0.38. For the sRANKL/OPG 
ratio correlations were r=0.69 over one year and r=0.48 over 14 years.
Discussion
This large prospective study is the first large-scale investigation on circulating sRANKL and 
the sRANKL/OPG ratio and breast cancer risk, and includes detailed analyses by hormone 
receptor subtype. A higher sRANKL/OPG ratio was associated with significantly higher risk 
of hormone receptor positive disease, particularly among women diagnosed at older ages. 
Results for sRANKL concentrations were similar for hormone receptor positive disease. The 
sRANKL/OPG ratio was inversely associated with hormone receptor negative breast cancer, 
consistent with our previous finding of a positive association between OPG concentrations 
and hormone receptor negative breast cancer (12).
In humans, RANKL protein or mRNA expression in normal breast tissue is higher in 
relatively high progesterone conditions – i.e., during luteal phase of the menstrual cycle and 
during pregnancy (10,11). In experimental models, RANKL expression in mammary cells of 
ovariectomized mice was elevated in both luminal and MaSC-enriched basal cells following 
injection of 17B-estradiol and progesterone, but not after injection of progesterone only (28). 
Similarly, progesterone injection strongly induced RANKL mRNA and protein expression in 
mammary tissue of non-ovariectomized, non-pregnant, nulliparous mice (i.e. in the presence 
of natural estrogens) (3). In addition, expression of both RANKL mRNA and protein in mice 
is induced by both prolactin and parathyroid hormone protein-related peptide (3) and 
RANKL mRNA expression is higher in luminal mammary cells of pregnant, as compared to 
virgin, mice (29).
In contrast, RANK expression was abundant in mouse mammary stem cells both mid-
pregnancy and following 17ß-estradiol plus progesterone treatment in ovariectomized mice 
(28,29). Treatment of mouse mammary stem cells and luminal cells with RANK-Fc, a 
RANKL antagonist, inhibited clonogenic activity of mouse mammary stem cells but not 
luminal cells (29). This is consistent with paracrine effects of RANK signaling, with 
progesterone inducing RANKL expression by luminal cells in the breast, which binds to 
RANK expressed on mammary stem cells.
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Both the absence of RANK and absence of overexpression of RANKL in mouse models 
result in non-functional mammary glands (3). Elongation of the ductal tree and side 
branching occur as normal in the mammary gland of RANKL deficient mice; however, 
alveolar differentiation and maturation are significantly impaired due to defective 
proliferation and increased apoptosis (3). Overexpression of RANKL in the virgin mouse 
mammary gland is sufficient to trigger side branching in the absence of the progesterone 
receptor (7,30,31).
Aside from the role of the RANK-axis in the normal mammary gland, experimental data 
suggest a role in mammary carcinogenesis (8,9). RANK expression has been shown to play 
a role in metastasis of primary breast and prostate cancer to sources of RANKL such as bone 
(4,5,32). RANK, RANKL, and OPG are expressed in a number of breast cancer cells lines 
and primary breast tumors (32–35), and expression of RANK protein or mRNA has been 
associated with higher cancer grade, hormone receptor negative/basal like tumors, and a 
shorter overall and bone metastasis free survival (36–39). RANKL expression in breast 
tumors has been linked to metastasis (33,36). Tumors expressing OPG, the decoy receptor 
for RANKL which prevents RANKL binding to RANK, correlate with lower tumor grade, 
longer overall and disease-free survival (37,40). This has not been universally observed, one 
study found lower tumor RANK and RANKL expression and higher tumor OPG expression 
to be associated with worse clinical outcomes (33), and one study observed an association 
between higher serum OPG protein expression and burden of metastatic disease (41).
Denosumab is a human monoclonal antibody that mimics the effect of OPG and inhibits 
binding of RANKL to RANK (42). It has been approved by the US Food and Drug 
Administration for treatment of osteoporosis in postmenopausal women and prevention of 
skeletal-related events in patients with bone metastases from solid tumors (16,42,43). It has 
also been shown to prevent bone loss in breast cancer patients treated with aromatase 
inhibitors (44). A phase III trial in early breast cancer patients at high risk of recurrence 
(NCT01077154) is currently underway. While denosumab delayed time to first fracture (45), 
outcomes relating to bone metastases and survival are yet to be reported. Breast tissue from 
BRCA1 carriers has been shown to be hyper-responsive to progesterone and inhibition of 
RANKL using denosumab has been shown to attenuate progesterone induced epithelial cells 
proliferation (Ki67 expression) in these tissues (17).
Epidemiologic data on the RANK-axis and breast cancer risk are sparse, with only one 
previous study evaluating circulating concentrations of sRANKL and ER+ breast cancer risk 
(15) and three previous investigations, including our own, evaluating circulating OPG and 
disease risk in the general population (12,13,15) and one in BRCA mutation carriers (14). 
Following experimental evidence, the hypothesized role of denosumab in breast cancer 
patients, and previous data on circulating RANK-axis member OPG and breast cancer, we 
hypothesized a positive association between sRANKL, and the sRANKL/OPG ratio, and 
breast cancer risk. In this first large-scale prospective study, we observed limited evidence 
for an association between sRANKL, or the sRANKL/OPG, and breast cancer risk, with an 
indication that higher sRANKL or sRANKL/OPG may be associated with higher risk of 
hormone receptor-positive disease. In line with our prior study, in which we observed a 
positive association between OPG and hormone-receptor negative breast cancer (12), the 
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sRANKL/OPG ratio was inversely associated with hormone-receptor negative disease risk in 
the current study. Results were similar in analyses adjusting for or stratifying by endogenous 
hormone concentrations or exogenous hormone use and menopausal status at blood 
collection. Although no statistically significant heterogeneity was seen by age of diagnosis, 
associations with breast cancer, similar in magnitude to those observed in the whole 
population, remained only among those aged >50 years at diagnosis (evaluated as a proxy 
for menopausal status).
The literature on RANK/RANKL signaling in breast development and carcinogenesis 
predominantly focuses on paracrine signaling in the breast, with only few studies reporting 
results on effects of circulating concentrations. One study found that inhibition of RANKL 
using a monoclonal antibody (OPG-Fc) reduces colony formation of estrogen and 
progesterone receptor negative cells expressing RANK, but not colony formation of 
hormone receptor positive cells of young adult mice (17). Similarly, injection of 
recombinant RANKL compared to control injection led to increased proliferation of 
mammary epithelial cells in mice lacking progesterone receptor, which was in turn inhibited 
by injection of OPG (30). Extending these findings to a BRCA1 mouse model, treatment 
with OPG-Fc delayed tumor onset compared to the control treatment (17).
It is plausible that circulating sRANKL concentrations are not representative of 
concentrations in the breast tissue itself, and concentrations in the normal breast are a more 
informative measure. While it is known that progesterone and prolactin are associated with 
RANKL expression in the breast, we saw no correlation between circulating concentrations 
of these hormones and sRANKL. To our knowledge, the association between circulating and 
breast tissue RANKL in humans has not previously been described. However, one prior 
study observed higher mammary RANKL in macaques treated with estrogen plus progestin, 
relative to control animals, while serum RANKL concentrations were similar in both groups 
(46). In contrast, both mammary and serum OPG were lower in the estrogen plus progestin 
treatment group, relative to controls. An additional limitation of our study is the use of a 
single measurement of sRANKL to characterize exposure. We observed moderate 
correlation (r= 0.60) between sRANKL measurements in samples taken one year apart, 
which is similar to previously reported correlations over five years (r= 0.63) (47). 
Correlations between sRANKL concentrations in samples taken 14 years study were 
relatively low. Correlations for the sRANKL/OPG ratio were somewhat stronger. This 
relatively low within-person reproducibility for sRANKL suggests one measure may not 
represent longer-term exposure and would result in non-differential misclassification, and an 
attenuation of the relative risk. In addition, the majority of RANKL in the human body is 
cell bound and not detectable in circulation (48). We observed relatively low sRANKL 
concentrations overall, and 8.3% (n=327) of the study population had concentrations below 
the limit of detection. In addition, previous work on RANKL and breast cancer has focused 
on BRCA-mutation carriers. We were unable to restrict our analyses to a high risk 
population as BRCA-status is unavailable in the EPIC cohort and information on family 
history of breast cancer is limited (61% missing, 4% reporting a positive family history). 
Further, we observed inter-batch CVs of 21.7%, reflecting measurement error, for OPG in 
postmenopausal women. This may have led to non-differential misclassification and 
attenuation of results. We observed relatively low concentrations of OPG, as compared to 
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others (13,14); however, this difference in absolute concentrations would not impact the 
relative ranking of participants in quintiles. Finally, although the number of cases included 
was large, only a limited number were diagnosed at a younger age, preventing us from 
evaluating risk of hormone receptor negative breast cancer in younger women (<50 years at 
diagnosis).
Conclusion
RANK-axis has been widely discussed as a potential target for breast cancer prevention (49) 
and, with the fully human antibody denosumab showing benefit for cancer patients in 
clinical trials there is increasing interest in RANKL as a target for prevention and treatment 
of breast cancer. However, this first large-scale investigation on circulating sRANKL in 
women provides only limited support for a role for circulating sRANKL in breast cancer 
risk. Further investigations in large, well-characterized populations are needed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Full Study Population, n 1976* 1976*
Baseline characteristics, median (range), or n (%))
Age at blood collection, years 56 (27-76) 56 (27-77)
Age at menarche, years 13 (8-20) 13 (8-19)
Premenopausal 460 (23%) 460 (23%)
Postmenopausal 1516 (77%) 1516 (77%)
      PMH use at blood collection† 758 (50%) 758 (50%)
      Age at menopause, years† 50 (27-63) 50 (21-63)
Completed term pregnancy 1675 (86%) 1709 (88%)
Age at first term pregnancy‡, years 25 (16-44) 24 (15-42)
BMI, kg/m2 24 (14-49) 24 (16-46)
sRANKL concentrations, pmol/L§ 0.11 (0.005, 1.67) 0.11 (0.005, 0.85)
OPG concentrations, pmol/L* 9.81 (2.94, 31.81) 9.84 (3.52, 32.86)






Age at diagnosis, years 61 (35-84)
Time between blood donation and diagnosis, years 4.7 (0.02-11.7)
*




Among women with completed term pregnancy
§
Lowest measured value was 0.01pmol/L; 327 observations (8.1%; 175 cases, 152 controls) had sRANKL concentrations below the LLOD of the 
assay, there were set to 50% the LLOD.
‖
PR status available for 74% of cases (sRANKL n=1461, sRANKL/OPG ratio n=1454); percentages represent percentage of total cases with ER 
and PR status available.
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